🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In the phase 3 CEPHEUS trial, patients with multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone, which led to a deeper and more durable increase in minimal residual disease responses Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 nature.com/articles/s4159…

Very important myeloma educational meeting for the first time in Africa organized by Noopur Raje. IMS serving educational needs globally #mmsm

Long-term MAIA #MMsm follow-up in Leukemia Journal 👏 New curves for octogenarians - even here, strong PFS benefit! No OS benefit, likely underpowering & competing risks. ⚠️ tweak: With IFM 2017-03, I’d argue that #downwithdex after 2 cycles is new SOC rather than OG MAIA D-Rd.

Raleigh! We’re kicking off the Healthy Churches 2030 Roadmap Tour with a FREE community health event! 🙌🏾 🔗 Register NOW: …ches2030roadmapraleigh.eventbrite.com #HC2030Tour #BlackHealthMatters #FaithInAction

Dr. Jeffrey Zonder and Dr. Aditi Sharma Karmanos Cancer Institute kicking off MSHO Precision Oncology Symposium Shirish Gadgeel with a fantaatic caae discussion for MM

#Myeloma Paper of the Day: Octogenarian myeloma pts have more comorbidities, higher Charlson comorbidity scores, lower rates of anti-MM therapy, reduced triplet/quadruplet use, and shorter median OS, while daratumumab positively influenced outcomes: pubmed.ncbi.nlm.nih.gov/40048737/. #mmsm

Supportive care is fundamental to an integrated treatment approach & requires coordinated expertise of several subspecialists familiar with AL amyloidosis International Society of Amyloidosis (ISA) expert panel guidelines pubmed.ncbi.nlm.nih.gov/39985185/

🧵Real-World Experience of Belantamab Mafodotin in Relapsed Refractory Multiple Myeloma 1/The study included 81 RRMM patients with a median of 5 prior lines of therapy. A significant proportion exhibited high-risk features: •92% were triple-class refractory. •45% were

#Myeloma Paper of the Day: Early daratumumab tx improves renal outcomes in newly diagnosed myeloma pts admitted w/ kidney injury; out of 9 who required dialysis, 4/7 (57.1%) and 6/7 (85.7%) were dialysis independent at 3 & 12 months, respectively: pubmed.ncbi.nlm.nih.gov/40085948/. #mmsm

1/ 🧵Check out our new study in Nature Genetics, which examines how precancerous conditions (MGUS/SMM) evolve into Multiple Myeloma, and offers new computational methods to predict progression risk and model cancer evolution. doi.org/10.1038/s41588…

The International Myeloma Working Group (IMWG) was formed in 2002 by International Myeloma Foundation bringing together myeloma experts committed to working together from around the world. IMWG.org Few diseases have a united collaborative group like this. The first papers were:

This is similar to car t in lymphoma… “plateau envy” no more?

What practical strategies can align care with patient and care partner goals, reduce #myeloma treatment burden, and improve outcomes? Join Dr. Sikander Ailawadhi and Dr. Craig Cole for a roundtable discussion on 6/18. Learn more & register here: bit.ly/43pqzUT #mmsm

Why so many smiles at #IMFIMWG ? Because the world's top myeloma experts are buzzing to share updates on groundbreaking research at the IMWG Summit! It's the start of something big for the future of #myeloma care.

#Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm

EMN guidelines for relapsed MM! #EHA2025

Register for tomorrow’s HCP Roundtable "Strengthening the Patient-Provider Partnership in Myeloma Care" at 1pm ET. Experts will share practical insights, communication tools, and team-based approaches to support #myeloma patient-centered care. bit.ly/43pqzUT #mmsm

This is our first Myeloma Society educational session in Northern Africa in collaboration with SMH.. 🙏 to our moroccan colleagues.. global education for #mmsm!

#Myeloma Paper of the Day: Real world study of belantamab mafodotin outcomes finds ORR 43% (21% VGPR or better), median PFS 3.8 mos, median OS 17.2 mos, median DOR 10.5 mos, reduced ORR & PFS (but better OS?) if prior BCMA tx, similar ocular tox: pubmed.ncbi.nlm.nih.gov/40575079/. #mmsm

Disparities in Accessing CAR-T and Bispecific Antibody Therapies | Craig... youtu.be/MCEbv_d5zdM?fe… #EHA25. #EHA2025 #mmsm Craig Emmitt Cole